Sophia Antipolis, France - Galderma's commitment to dermatology, and dermatology only, is nowhere more evident than in its sprawling, approximately 24,000-square-foot research and development facility in the south of France.
Hidradenitis Suppurativa in Transgender and Gender-Diverse Patients and Hormone Therapy
ReV Up Your Vitiligo Treatment Strategies
Radiation Therapy Associated With Elevated Skin Cancer Risk in Patients With Breast Cancer
The Cutaneous Connection: Splish, Splash, AD Management Starts in the Bath
Dupilumab for Atopic Dermatitis: 7 Years Later
Reviewing Late-Breaking Research From AAD 2024